文献速递临床试验与 GCP基础与转化研究

SARS-CoV-2特异性T细胞治疗重症COVID-19:一项随机1/2期试验

SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.
PubMed 文献 · Nat Med · 2023-07-17

在Delta变异株流行期间,开展随机(2:1)、开放标签1/2期试验,评估现货型、部分HLA匹配的康复者供者来源SARS-CoV-2特异性T细胞(CoV-2-STs)联合标准治疗(SoC)治疗重症COVID-19的安全性和疗效。90例受试者随机接受CoV-2-ST+SoC(n=60)或仅SoC(n=30)。CoV-2-ST+SoC安全且耐受良好,达到主要复合终点:恢复率65% vs 38%(P=0.017),恢复率比1.71(95%CI 1.03-2.83,P=0.036),并达到CoV-2-ST显著扩增的共同主要目标(P=0.047)。

要点

  • CoV-2-ST+SoC组恢复率65% vs SoC组38%(P=0.017),恢复率比1.71(95%CI 1.03-2.83,P=0.036)。
  • 中位恢复时间CoV-2-ST+SoC组11天 vs SoC组未达到(P=0.052)。
  • CoV-2-ST+SoC安全且耐受良好,并达到CoV-2-ST显著扩增的共同主要目标(P=0.047)。

核心结论

  • 在重症COVID-19住院患者中,过继免疫治疗CoV-2-STs可行且安全;需要更大规模试验以强化其在重症COVID-19中临床获益的初步证据。

研究设计与样本

  • 随机(2:1)、开放标签、1/2期试验,在Delta变异株流行期间比较CoV-2-ST+SoC与仅SoC。
  • 经过剂量递增的1期安全性研究后,90例受试者随机接受CoV-2-ST+SoC(n=60)或仅SoC(n=30)。
  • 共同主要目标为恢复时间与30天恢复率的复合终点,以及CoV-2-ST+SoC组相较于SoC组CoV-2-STs的体内扩增。
  • 关键次要目标为第60天生存。

主要发现

  • CoV-2-ST+SoC治疗安全且耐受良好。
  • 达到主要复合终点:恢复率CoV-2-ST+SoC组65% vs SoC组38%(P=0.017);中位恢复时间CoV-2-ST+SoC组11天 vs SoC组未达到(P=0.052);恢复率比1.71(95%CI 1.03-2.83,P=0.036)。
  • 达到CoV-2-ST显著扩增的共同主要目标:CoV-2-ST+SoC组 vs SoC组,P=0.047。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更大规模试验以强化其在重症COVID-19中临床获益的初步证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite advances, few therapeutics have shown efficacy in severe coronavirus disease 2019 (COVID-19). In a different context, virus-specific T cells have proven safe and effective. We conducted a randomized (2:1), open-label, phase 1/2 trial to evaluate the safety and efficacy of off-the-shelf, partially human leukocyte antigen (HLA)-matched, convalescent donor-derived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells (CoV-2-STs) in combination with standard of care (SoC) in patients with severe COVID-19 compared to SoC during Delta variant predominance. After a dose-escalated phase 1 safety study, 90 participants were randomized to receive CoV-2-ST+SoC (n = 60) or SoC only (n = 30). The co-primary objectives of the study were the composite of time to recovery and 30-d recovery rate and the in vivo expansion of CoV-2-STs in patients receiving CoV-2-ST+SoC over SoC. The key secondary objective was survival on day 60. CoV-2-ST+SoC treatment was safe and well tolerated. The study met the primary composite endpoint (CoV-2-ST+SoC versus SoC: recovery rate 65% versus 38%, P = 0.017; median recovery time 11 d versus not reached, P = 0.052, respectively; rate ratio for recovery 1.71 (95% confidence interval 1.03-2.83, P = 0.036)) and the co-primary objective of significant CoV-2-ST expansion compared to SοC (CoV-2-ST+SoC versus SoC, P = 0.047). Overall, in hospitalized patients with severe COVID-19, adoptive immunotherapy with CoV-2-STs was feasible and safe. Larger trials are needed to strengthen the preliminary evidence of clinical benefit in severe COVID-19. EudraCT identifier: 2021-001022-22 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Papadopoulou A, Karavalakis G, Papadopoulou E, et al. SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial. Nat Med. 2023. PMID: 37460756. doi:10.1038/s41591-023-02480-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。